Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDRH matrix team likely to be scrapped

This article was originally published in The Silver Sheet

Executive Summary

Two years after going live, CDRH's matrix team - a structure of network leaders tasked with keeping pre- and post-market offices communicating - is likely on its way out. "We did an internal assessment of the matrix structure and concluded it is probably not the best organization [for us] right now," CDRH Director Jeffrey Shuren said at a June 22 FDA "town hall" meeting in Woburn, Mass., noting that the matrix "is very challenging to maintain." CDRH plans to issue a report soon that will explore alternative organizational options, he said. The matrix brings together pre-market reviewers, adverse event analysts, scientific researchers and others to evaluate safety risks for different device types ("The Silver Sheet" September 2009). Although the matrix may not be the answer, Shuren affirmed that the goal of breaking down barriers between "siloed" groups within the center is correct. He cited the recent creation of two new deputy director positions in the Office of the Center Director, one for science and one for policy, as a step toward greater alignment on those issues throughout CDRH's various offices. Those posts have yet to be filled, however

You may also be interested in...



US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says

The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.

Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?

EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.

Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?

Insurance plans put on notice that CMS is concerned about restrictions on drugs with negotiated prices, but it’s not clear what the agency can or will do about it.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel